The global spread of infectious diseases was influenced by human movement dynamics, particularly for highly transmissible diseases like COVID-19. Asymptomatic COVID-19 cases lacked symptoms before diagnosis, posing a challenge for containment. Their contribution to air travel remains understudied. This retrospective cross-sectional study investigated the role of asymptomatic COVID-19 cases in air travel and their impact on the global spread of the virus. Through our analysis of 11,775 COVID-19 cases in Hong Kong (January 2020 to April 2021), log-binomial regression models assessed the association between asymptomatic status and air travel behavior 14 days before diagnosis. The Wilcoxon rank-sum test compared median flight durations between asymptomatic and symptomatic cases. Results revealed two-thirds of cases with air travel history were asymptomatic, with asymptomatic airport or flight crew ten times more likely to travel than symptomatic counterparts (adjusted PRR=10, 95% CI: 4.00 to 25.00). For non-crew individuals, the adjusted PRR was 1.14 (95% CI: 1.12 to 1.16). Median flight duration for asymptomatic cases was 4.6 person-hours shorter than symptomatic ones (p<0.01). These findings highlight the significant contribution of asymptomatic cases to air travel and suggest under-detection during initial travel restrictions. Our study emphasizes proactive public health measures early in pandemics involving airborne infections, irrespective of symptom presentation.

The authors have declared no competing interest.

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data is available in the public source and repository.